Scotiabank analyst Louise Chen initiated coverage of Cogent Biosciences (COGT) with an Outperform rating and $17 price target Positive readouts from three registrational studies this year could significantly increase confidence in Cogent’s potentially BIC KITis and drive the stock higher, the firm says. Positive data from Part 1 of these studies help de-risk the upcoming readouts. These assets have U.S. peak sales potential of $3B, but Scotiabank does not believe this is reflected in Cogent’s valuation yet.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential
- Cogent Biosciences Reports 2024 Financial Results and Clinical Progress
- Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial
- Cogent Biosciences price target lowered to $8 from $10 at Baird
- Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating